JOINT STOCK COMPANY OLAINFARM
(UNIFIED REGISTRATION NUMBER 40003007246)
CONSOLIDATED ANNUAL REPORT
FOR THE PERIOD ENDED 30 JUNE 2012

PREPARED IN ACCORDANCE WITH INTERNATIONAL FINANCIAL REPORTING STANDARDS, AS ADOPTED BY THE EU

Contents

Contents	2
General information	3
Major shareholders	12
Statement of Responsibility of the Management	21
Statement of consolidated comprehensive income	22
Consolidated statement of financial position	23
Consolidated statement of financial position	24
Consolidated statement of cash flow	25
Statement of consolidated changes in equity	26
Notes to the consolidated financial statements	27

Address: Rūpnīcu iela 5, Olaine, LV-2114 Unified registration number: 40003007246

General information

Name of the Parent Company OLAINFARM

Legal status of the Parent Company JOINT STOCK COMPANY

Unified registration number, place and date of registration of the Parent

date of registration of the Parent

Company

40003007246

Riga, 10 June 1991 (re-registered on 27 March 1997)

Registered office of the Parent Company Rūpnīcu iela 5

Olaine, Latvia, LV-2114

Major shareholders of the Parent

Company

Valērijs Maligins - 29.24%

SIA Olmafarm - 42.56%

AS Swedbank Clients Account – 12.64%

Address: Rūpnīcu iela 5, Olaine, LV-2114 Unified registration number: 40003007246

Board

Supervisory Council elects the Management Board of AS Olainfarm for five years. When selecting the members of the Management Board, Council assesses experience of candidates in team management, in particular area of responsibility of candidate and in pharmaceutical sector in general.

Valērijs Maligins, Chairman of the Board



Valērijs Maligins is the Chairman of Management Board of Olainfarm. He has obtained a degree of a Doctor of Economics at NewPort Interational University, Baltic Center (2007), as well as Master of economics and social sciences (University of Latvia, 2002), Bachelor of economics and finances (RSEBAA 1998). V. Maligins has more than 20 years of experience in pharmaceutical sector, 14 of them from management positions at AS Olainfarm.

Positions held in other companies: SIA Olmafarm, Chairman of the Board Hunting Club Vitkupe, Board Member

Participation in other companies:

SIA Lano Serviss (25.04%)

SIA Vega MS (60%)

SIA Briz (12.48%)

SIA Olfa Press (45%)

SIA Carbochem (50%)

SIA Aroma (75%)

SIA Olmafarm (100%)

SIA Escargot (33.50%)

SIA Olalex (50%)

Number of shares of AS Olainfarm owned (as of June 30, 2012):

- Directly: 4 118 244

- Indirectly (through SIA Olmafarm): 5 994 054

- Total: 10 112 298

Jelena Borcova, Board Member



Jelena Borcova is a member of Company's Management Board and a qualified person. J. Borcova has a degree in Pharmacy (Medical Institute of Riga, 1988). J. Borcova has more than 15 years of experience in pharmaceutical production.

Positions held in other companies: SIA Carbochem, Board Member (till 21 of June, 2012) Participation in other companies: none

Number of shares of AS Olainfarm owned (as ofJune 30, 2012): 0

Inga Liščika



Inga Liscika is a member of Company's Management Board and a Finance director. I. Liscika has been studying the Professional Management programme at English "Open University". I. Liscika is a Master of Business Economics (Riga Technical University 1997) and a civil engineer (1995). I. Liscika has been working at AS Olainfarm for more than 10 years.

Positions held in other companies:
SIA Pharma and Chemistry Competence Centre of Latvia, Council Member
AS Lege Artis Rīga, Council Member;
SIA First Class Lounge, Board Member
SIA Olalex, Board Member
SIA "Carbochem", Board Member (from 21 of June, 2012)

Participation in other companies: none

Number of shares of AS Olainfarm owned (as of June 30, 2012): 1 302

Salvis Lapiņš



Salvis Lapins is a member of Company's Management Board, manager of Investor relations. He has been studying business in RSEBAA and law in University of Latvia. He has been actively working in financial and pharmaceutical sectors since 1995.

Positions held in other companies: none

Participation in other companies: SIA Baltic Team-Up (50%)

Number of shares of AS Olainfarm owned (as of June 30, 2012): 83 653





Veronika Dubicka (Veranika Dubitskaya) since 2005 works in Company representation in Belarus. Till 2006 the madam Dubitsky held a post of the medical representative, since 2006 till July, 2009 a post of the manager, and since July, 2009 till May, 2011 was the principal of representation of Company in Belarus.

Positions held in other companies: none

Participation in other companies: none

Number of shares of AS Olainfarm owned (as of June 30, 2012): 0

Address: Rūpnīcu iela 5, Olaine, LV-2114 Unified registration number: 40003007246

Council

Supervisory Council of AS Olainfarm is elected by General Meeting of Shareholders for 5 years. Supervisory Council is a supervising institution, representing interests of shareholders between meetings of shareholders. Main tasks of the Supervisory Council include supervising the Mnagement Board and these are the main requirements that are taken into account when shareholders propose new members of the Council.

Supervisory Council sets the remuneration for the mambers of the Management Board, while the remuneration of the Council itself is set by the General Meeting of Shareholders.

Valentina Andreeva

Valentina Andreeva, the chairman of the council Valentina Andreeva, the Doctor of Economics of the Riga technical university (Dr.oec.) - 2006, and also has degree of the master of economic sciences in a management of the enterprise activity, received in the Riga technical university in 2001, a speciality of the engineer-economist which it has received in 1976 at the Riga polytechnical institute.

Positions held in other companies: none

Participation in other companies: none

Number of shares of AS Olainfarm owned (as of June 30, 2012): 0

Jelena Dudko, Deputy Chairperson of the Council

Jelena Dudko is a Strategic Development and Marketing Director of pharmaceutical company Olfa. In 1996 J.Dudko graduated post graduate course in Faculty of Therapy and Hematology of Kiev Medical Academy.

Positions held and participation in other companies: none

Number of shares of AS Olainfarm owned (as June 30, 2012): 0

Aleksandrs Raicis

Aleksandrs Raicis is a Deputy Director of Latvian Association of Medical Wholesalers and Pharmaceutical Director of SIA "Briz". A.Raicis has a degree in Pharmacy from Riga Medical Institute (1984).

Positions held in other companies: SIA BRIZ, Board Member

Participation in other companies: SIA SUPEREURO (17%) SIA VIP Pharma (50%) SIA Recesus (30%). SIA Briz (10.96%)

Number of shares of AS Olainfarm owned (as June 30, 2012): 0

Volodimir Krivozubov

Volodimir Krivozubov is a Director of Ukrainian OOO "Torgoviye Tehnologii". V.Krivozubov has a medical degree from A. Bogomolec Kiev Medical Institute (1984).

Positions held in other companies:

OOO Torgovije Tehnologii (Ukraine), General Director

Participation in other companies: none

Number of shares of AS Olainfarm owned (as of June 30, 2012): 0

Signe Baldere-Sildedze (till April 27, 2012)

Since 2007 S.Baldere-Sildedze was a Commercial Director of SIA Louvre. In 1997 S.Baldere-Sildedze graduated International School of Hospitality and Tourism in Switzerland.

Positions held in other companies: SIA Louvre, Board Member

Participation in other companies: SIA Louvre (50%)

Number of shares of AS Olainfarm owned (as of June 30, 2012): 0

Tālis Talents (no 2012.gada 27.aprīļa)

Talis Talents completed higher education in Riga Medical Institute, Faculty of Pharmacy (1980th year), the pharmacist profession, won the 1992 Manager's qualifications Iscra Business School in Tokyo, Japan.

Positions held in other companies: none

Participation in other companies: none

Number of shares of AS Olainfarm owned (as of June 30, 2012): 0

Movements in the Board during the year 1 January 2012 through 30 June 2012

None

Movements in the Council during the year 1 January 2012 through 30 June 2012

On April 27, 2012 "Olainfarm" Shareholder Meeting Board instead of member

S. Baldere- Sildedze elected Tālis Talent.

Address: Rūpnīcu iela 5, Olaine, LV-2114 Unified registration number: 40003007246

Subsidiaries

SIA Ozols JDR (100%)

Zeiferta iela 18B, Olaine, LV-2114, from 18/10/2010

SIA Olainfarm energija (50%)

Rūpnīcu iela 5, Olaine, LV-2114, from 15/09/2010

SIA Pharma and Chemistry Centre of Latvia (11%)

Dzirnavu iela 93-27, Rīga, LV-1011, from 11/08/2010

SIA JUKO 99 (100%)

Celmu iela 3, Rīga, LV-1079, from 28/10/2011

SIA Ilmas Aptieka (100%)

Krišjāņa Barona iela 117, Rīga, LV-1012, from 02/11/2011

SIA Veritas-Farm (100%)

Valkas iela 2a, Daugavpils, LV-5417, from 06/12/2011

AS Lege Artis Rīga (100%)

Rūpnīcu iela 5, Olaine, LV-2114, from 01/12/2011

SIA First Class Lounge (51%)

Baznīcas iela 20/22-10, Rīga, LV-1010, from 08/12/2011

SIA Inula Farma (100%)

Nīcgales iela 47A, Rīga, LV-1035, from 21/12/2011

SIA Vita Plus Aptieka (100%)

Dārza iela 6, Priekuļi, Priekuļu nov., LV-4126, from 22/12/2011

SIA Teriaks Plaviņu aptieka (100%)

Odzienas iela 1, Priekuļi, Priekuļu nov., LV-5120, from 09/02/2012

"Aptieka Rudens 10" (100%)

Rūpnīca iela 5, Olaine, LV-2114, from 21.03.2012.

SIA "Rudens Laiks" (100%)

Rūpnīca iela 5, Olaine, LV-2114, from 21.03.2012.

SIA "Esplanāde Farm" (100%)

Kandavas iela 4, Daugavpils, LV-5401, from 17.07.2012.

"OLAINFARM ILJAČ VE TIBBI URJUNLERI SANAJI VE TIDŽARET LIMITED

ŠIRKETI" (99%)

Kirbis Šehitleri. Džaddesi Nr.134/1, Daire: 204, Alsandžaka /IZMIRA, Turcija.

Core business activity Manufacture of basic pharmaceutical products and pharmaceutical preparations

Audit Committee Žanna Karaseva

Address: Rūpnīcu iela 5, Olaine, LV-2114 Unified registration number: 40003007246

Consolidated annual report for the period ended 30 June 2012

Financial year 1 January – 30 June 2012

Auditors Iveta Vimba SIA Ernst & Young Baltic Member of the Board Muitas iela 1A, Riga

Latvian Certified Auditor Latvia, LV-1010
Certificate No. 153. Licence No. 17

Company does not have any other contractual relationships either with its auditor or

auditing company.

Major shareholders

	Holding (%)
Swedbank AS Clients Account Formerly AS Swedbank	12.64%
Olmafarm, SIA	42.56%
V.Maligins	29.24%
Other shareholders	15.56%
Total	100.00%

MANAGEMENT REPORT

General information

During the reporting period changes have been made to the composition of the Concern and it now consists from parent company a/s "Olainfarm", its daughter companies SIA "Ozols JRD", whose major activities will be related to organizing sports and active leisure events in Olaine, daughter company "Olainfarm Energija", that will be engaged in production of electric energy using cogeneration technologies, travel agency "First Class Lounge" and pharmaceutical retail companies SIA "Ilmas Aptieka", SIA "Juko 99", SIA "Veritas Farm", SIA "Inula Farma", a/s "Lege Artis" and SIA "Vita Plus". In February 2012, shares in SIA "Teriaks Pjaviņu Aptieka", but in June 2012 shares in SIA "Rudens Laiks" and SIA "Rudens 10" were also purchased.

The Group is one of the biggest pharmaceutical companies in Latvia with nearly 40 years of experience in production of medication and chemical and pharmaceutical products. A basic principle of Group's operations is to produce reliable and effective top quality products for Latvia and the rest of the world. Products made by the Group are being exported to more than 30 countries of the world, including the Baltics, Russia, other CIS, Europe, Asia, North America and Australia.

Corporate mission and vision

Corporate mission:

JSC "Olainfarm" is one of the biggest manufacturers of finished drug forms chemical products in the Baltics. The keystone of our work is manufacturing of reliable and effective high quality products to the whole world. We are about fair and effective cooperation with our customers – patients, doctors, pharmacists and other partners. In achievement of our goals we are creating a team of highly qualified, socially secured and well-motivated employees. Our priority is organizing an environmentally friendly manufacturing and constant increase of the Company's shareholders value.


Corporate vision:

We are aiming to become the leading manufacturer of finished drug forms and chemical-pharmaceutical products in the Baltics and to make our products known and available worldwide.

Financial results


During the 2nd quarter of 2012 the sales of cocompany grew by 10% and reached 10.6 million lats (15.2 million euro) which makes this the most successful second quarter in a corporate history.

Sales by Quarters, thsnd. LVL




First six months combined have also been the best in corporate history in terms of sales. Consolidated six months sales have reached 11.7 million lats (32.2 million euro), which represents an increase by 27%\$ compared to similar period of 2011.


Sales in Six Months, thend.



During 1st half of 2012 sales to all our key markets continued growing, except Belarus, where sales remained stable. The biggest sales increases were achieved in Taiwan, where sales grew by 596%, in Latvia, where sales grew by 313%, and the UK, where sales grew by 75%. Major sales markets of AS "Olainfarm" in six months of 2012 were Russia, Latvia, Ukraine, Belarus and the UK.




During the first half of 2012 the share of bestselling products Neiromidin® in total sales stabilized at the level of 22%. Share of all the other products has also remained relatively unchanged. Product portfolio is still well diversified, as 10 best-selling products make up 89% of total sales.




Since pharmacies owned by the company are having big and increasing impact on company's financial indicators, and as a business they have smaller margins and are subject to bigger seasonal fluctuations, the Company has not been able to set a new profit record for the 2nd quarter alone. During the 2nd quarter the net profit of the company has reached 1.3 million lats (1.8 million euro), which is a decrease by 13% compared to 2nd quarter of 2011.

Profit by Quarters



Although no profit record was set for the 2nd quarter alone, first half of the year combined has been the corporate best-ever in terms of the net profit. During first dix months of 2012 the company has made a net profit of 3.7 million lats (5.3 million euro), which is by 15% more than during the 1st half of 2011.

Six Months Profit, thend.



Other financial indicators of the company have experienced similar developments.

Financial indicator	30.06.2012.	30.06.2011.	% to previous period
Sales (LVL)	22 677 582	17 830 534	127%


Financial indicator	30.06.2012.	30.06.2011.	% to previous period
			periou
Net profit (LVL)	3 692 776	3 207 698	115%
EBITDA (LVL)	5 350 644	5 061 473	106%
EBIT (LVL)	4 311 382	4 124 938	105%
Sales (EUR)	32 267 292	25 370 564	127%
Net profit (EUR)	5 254 347	4 564 144	115%
EBITDA (EUR)	7 613 280	7 201 827	106%
EBIT (EUR)	6 134 544	5 869 258	105%
EBITDA margin, %	24	28	
Net margin, %	16	18	
EBIT margin, %	19	23	
Profit, last 12 months (LVL)	7 396 293	4 963 051	149%
Profit, last 12 months (EUR)	10 523 977	7 061 785	149%
EBITDA, last 12 months (LVL)	10 643 996	8 348 631	127%
EBITDA, last 12 months (EUR)	15 145 041	11 879 032	127%
ROA, % (last 12 months)	16,3	12.9	
ROE, % (last. 12 months)	23,7	21.1	
Current ratio	3,2	2,6	
EPS, LVL (quarter)	0,26	0,23	115%
EPS, EUR (quarter)	0,37	0,32	115%
Share price, end of the period (LVL)	2,95	3,005	98%
Share price, end of the period (EUR)	4,197	4,276	98%
P/E, last 12 months	5,6	8,5	
Market capitalisation at the end of the period	41 550 980	42 325 659	98%
(LVL) Market capitalisation at the end of the period (EUR)	59 121 718	60 223 987	98%
P/B	1,33	1,8	

Annual meeting of shareholders of A/s "Olainfarm" held on April 27, 2012 approved operating plan of the Concern. According to it, sales of the Concern in 2012 are planned to be 48 million lats (68.3 million euros), but the net profit will reach 8.6 million lats (12.24 million euros). According to this unaudited report for 1st half of 2012, during the first six months 47.2% of annual sales target and 42.9% of annual profit target is met.

Shares and stock market

Rapid improvement of Company's financial indicators over the last three years are reflected in fluctuations of price of Company's shares on NASDAQ OMX Riga, as during this period the price of share increased by more than 500%. During the reporting period price of share mostly fluctuated around 3 lats (4.27 euros), however, at the beginning of May it reached the highest price this year of 3.18 lats (4.53 euro). As this report is being produced, the share price fluctuates at the level of 3 lats (4.30 euros). During the first half of 2012 price of share of a/s "Olainfarm" has been fluctuating between 2.495 and 3.18 lats (3.55 and 4.525 euros).

Price of shares of "Olainfarm" on NASDAQ OMX Riga (LVL) (July 2009 - June 2012)



During the first half of this year price of share of a/s "Olainfarm" increased significantly more than OMX Riga index. During these six months OMX Riga index increased by a mere 0.57%, while price for share of "Olainfarm" by 20.16%.


Rebased price of Olainfarm share vs. rebased OMX Riga index (1st half of 2012)



⁻⁻ OMX Riga

⁻⁻ AS "Olainfarm"

Trading of Shares in NASDAQ OMX Riga, mln.



Since April 12, 2012 bank Finasta provides liquidity for company's shares on Nasdaq OMX Riga. According to the agreement signed with Finasta, it will constantly ensure supply and demand for shares worth 2000 lats, with a spread of 4%. Possibly this development, along with stable financial indicators of the company has been among the reasons, why number of shares of "Olainfarm" traded during 6 months of this year has increased by more than 30% to 668 thousand, for the total value of nearly 2 million lats.

Development

During 1st half of 2012, 20 registration cases in 16 countries, mostly Central Asian countries of the FSU were completed,.

An eCTD system has been successfully implemented in a Company and the first file in such format has been submitted (Memodex 10mg) for registration in 10 EU countries. For the first time Olainfarm is registering medicines according to DCP procedure with Latvia being a reference country.

In June 2012, the Company has obtained a license for production of the medicines for clinical trials.

In August 2012, State Agency for Medicines repeatedly confirmed, that production of APIs of memantine and amantadine in "Olainfarm" meets all the requirements of modern Good manufacturing practice.

Environment

In order to further minimize possible environmental damage risk, in 1st half of 2012 the company stopped using carcinogenic benzene in its production. According to the requirements of REACH directive, use of benzene in industrial production will be significantly limited in the nearest future throughout European Union.

Social responsibility

Since 2011 the Company has started supporting SOS Children village in region of Olaine. This year the company will support provision of psychological assistance for families affected by crisis. Also significant support is being provided to Football club of Olaine, Tennis School of Marupe. The Company also supports construction of the Orthodox church in Olaine.

Events after the end of the reporting period

On April 27, 2012, Annual General Meeting of shareholders of the Company decided to pay dividends for a second consecutive year. The decision was made to pay 867 793.50 lats (1 234 758.91 euro) in dividends, which represents approximately 12.5% of the net profit made in 2011. 6.16 santims (8.76 euro cents) per share will be paid.

August 3rd, 2012 was a record date and August 8th, 2012 was the payment date of the dividends declared for 2011. 6.16 santims (8.76 euro cents) per share were paid. This has been the second consecutive year when the company has paid dividends to its shareholders.

On August 15, the Company has signed an Agreement On Project Implementation with Latvian Investment and Development Agency. According to this agreement the Company will make high value-added investments into production of nitrofuranes and 35% of the eligible project costs will be funded by LIDA. Total cost of the project is 5.88 million lats and the completion is scheduled in 2015.

In July 2012 the Company has purchased 100% shares in SIA "Esplanāde Farm", a company that owns three pharmacies in Daugavpils. With this purchase the total number of pharmacies has been increased to 39.

In July 2012, AS "Olainfarm" was named the best Latvian company listed on Baltic stock exchanges and was awarded "Baltic Corporate Excellence Award 2012". AS "Olainfarm" this year was named second best company in the entire Baltics. During the last three years AS "Olainfarm" has demonstrated a very impressive improvement in valuations for Baltic Corporate Excellence Awards", it has climbed from position 19 in the Baltics in 2010, to position 8 in 2011 to the second place this year.

The financial reports were approved by the Board of the Parent company and on its behalf they are signed by



31 August 2012

Statement of Responsibility of the Management

The Management Board prepares financial statements for each financial year which give a true and fair view of the state of affairs of the Group, the cash flows and the results of the Group for that period in accordance with International Financial Reporting Standards as adopted by the EU. In preparing those financial statements, they:

- select suitable accounting policies and then apply them consistently;
- make judgments and estimates that are reasonable and prudent;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the Group will continue in business.

The Management Board is responsible for keeping proper accounting records, which disclose with reasonable accuracy at any time the financial position, financial performance and cash flows of the Parent Company and the Group and enable them to ensure that financial statements drawn up from them comply with International Financial Reporting Standards as adopted by the EU.

For the Board of JSC Olainfarm:



31 August 2012

Statement of consolidated comprehensive income

Notes	•	•	-	2011.II.quarter EUR
3	22 677 582			
	394 209	560 909		
4	507 604	722 255	286 307	, ,
	(4 883 905)	(6 949 171)	(1 866 836)	(2 656 268)
	(1 158 887)	(1 648 948)	(972 067)	(1 383 127)
	(6 042 792)	(8 598 119)	(2 838 903)	
	,	,	,	,
8	(3 676 043)	(5 230 538)	(2 822 997)	(4 016 763)
8	(857 163)	(1 219 633)	(659 272)	(938 060)
	(4 533 206)	(6 450 171)	(3 482 269)	(4 954 823)
10,11.	(1 039 262)	(1 478 737)	(936 535)	(1 332 569)
5	(7 652 753)	(10 888 887)	(6 548 771)	(9 318 062)
6	27 787	39 537	21 482	,
7	(103 437)	(147 178)	(160 456)	(228 308)
	4 235 732	6 026 901	3 954 218	5 626 345
	(542 956)	(772 557)	(743 684)	(1 058 167)
	3 692 776	5 254 347	3 210 534	4 568 178
9	0.262	0.373	0.228	0.324
	3 4 8 8 8 10,11.	LVL 3 22 677 582 394 209 4 4 507 604 (4 883 905) (1 158 887) (6 042 792) 8 8 (3 676 043) (4 533 206) (4 533 206) 10,11. (1 039 262) 5 (7 652 753) 6 27 787 7 (103 437) 4 235 732 (542 956) 3 692 776	LVL EUR 3 22 677 582 32 267 292 394 209 560 909 4 507 604 722 255 (4 883 905) (6 949 171) (1 158 887) (1 648 948) (6 042 792) (8 598 119) 8 (3 676 043) (5 230 538) 8 (857 163) (1 219 633) (4 533 206) (6 450 171) 10,11. (1 039 262) (1 478 737) 5 (7 652 753) (10 888 887) 6 27 787 39 537 7 (103 437) (147 178) 4 235 732 6 026 901 (542 956) (772 557) 3 692 776 5 254 347	LVL EUR LVL 3 22 677 582 32 267 292 17 830 534 394 209 560 909 (217 171) 4 507 604 722 255 286 307 (4 883 905) (6 949 171) (1 866 836) (1 158 887) (1 648 948) (972 067) (6 042 792) (8 598 119) (2 838 903) 8 (3 676 043) (5 230 538) (2 822 997) 8 (857 163) (1 219 633) (659 272) (4 533 206) (6 450 171) (3 482 269) 10,11. (1 039 262) (1 478 737) (936 535) 5 (7 652 753) (10 888 887) (6 548 771) 6 27 787 39 537 21 482 7 (103 437) (147 178) (160 456) 4 235 732 6 026 901 3 954 218 (542 956) (772 557) (743 684) 3 692 776 5 254 347 3 210 534

Jelena Borcova Member of the Board

The accompanying notes form an integral part of these financial statements.

For the Board of JSC Olainfarm:



Address: Rūpnīcu iela 5, Olaine, LV-2114 Unified registration number: 40003007246

Consolidated statement of financial position

	AS	SSETS			
	Notes	30.06.2012	30.06.2012	30.06.2011	30.06.2011
NON-CURRENT ASSETS		LVL	EUR	LVL	EUR
Intangible assets					
Goodwill	10	2 178 102	3 099 160	503 930	717 028
Patents	10	1 320 608	1 879 056	5 686 192	8 090 722
	10	3 980 000	5 663 030	-	-
Other intangible assets	10	1 078 098	1 533 995	546 095	777 023
Prepayments for intangible assets		176 619	251 306	331 289	471 382
TOTAL		8 733 427	12 426 547	7 067 507	10 056 155
Property, plant and equipment					
Land, buildings and constructions	11	7 545 088	10 735 693	5 887 342	8 376 933
Equipment and machinery	11	2 740 124	3 898 845	2 177 799	3 098 729
Other tangible assets	11	1 031 638	1 467 889	597 641	850 367
Construction in progress	11	692 794	985 757	213 656	304 005
Prepayments for property, plant and equipment		84 685	120 496	467 725	665 513
TOTAL		12 094 329	17 208 680	9 344 162	13 295 546
Financial assets					
Other securities and investments		7	10	-	-
Investments in related companies		1 000	1 423	1 650	2 348
TOTAL		1 007	1 433	1 650	2 348
TOTAL NON-CURRENT ASSETS		20 828 763	29 636 660	16 413 318	23 354 048
CURRENT ASSETS					
Inventories					
Raw materials		1 290 189	1 835 775	771 425	1 097 639
Work in progress		3 645 004	5 186 373	3 665 906	5 216 114
Finished goods and goods for resale		3 247 762	4 621 148	1 945 148	2 767 696
Goods in transit		-	-	70 068	99 698
Prepayments for goods		127 575	181 523	92 571	131 717
TOTAL	12	8 310 530	11 824 819	6 545 117	9 312 863
Receivables					
Trade receivables	13	13 312 528	18 942 021	10 947 028	15 576 218
D : 11 (11)		000 400	445 700	450 407	000 447

292 183

341 585

439 204

668 645

178 049

15 232 194

24 554 788

45 383 551

REPUE

1 012 064

415 739

486 032

624 931

951 396

253 341

21 673 459

1 440 037

34 938 316

64 574 975

159 127

355 904

14 419

823 426

2 542 615

1 114 683

15 133 776

22 502 319

38 915 638

For the Board of JSC Olainfarm:

Prepayments to suppliers

Other receivables

Prepaid expense

Cash

Receivables from related companies

Current loans to management and employees

TOTAL

TOTAL CURRENT ASSETS

Jelena Borcova Member of the Board OlainFarm

14

31August 2012

TOTAL ASSETS

226 417

506 406

20 516

3 617 815

1 586 051

21 533 424

1 171 630

32 017 917

55 371 965

Address: Rūpnīcu iela 5, Olaine, LV-2114 Unified registration number: 40003007246

Consolidated statement of financial position

	ו חוא	IAD	ILITIES
1 I I F	แนบเ	_I ADI	ILIIIEO

	Notes	30.06.2012	30.06.2012	30.06.2011	30.06.2011
EQUITY		LVL	EUR	LVL	EUR
Share capital	15	14 085 078	20 041 260	14 085 078	20 041 260
Share premium		1 759 708	2 503 839	1 759 708	2 503 839
Retained earnings/ (accumulated deficit):					
brought forward		11 628 975	16 546 541	4 454 134	6 337 662
for the period		3 692 776	5 254 347	3 210 534	4 568 178
TOTAL EQUITY		31 166 537	44 345 987	23 509 453	33 450 939
Minority interest		370	526	-	-
LIABILITIES					
Non-current liabilities					
Loans from credit institutions	16	5 288 862	7 525 373	2 830 842	4 027 925
Deferred corporate income tax liabilities		1 134 551	1 614 321	916 370	1 303 877
Finance lease liabilities	17	16 810	23 918	12 839	18 268
Long term payables		-	-	2 453 050	3 490 376
Loan from shareholder		-	-	540 237	768 688
TOTAL		6 440 223	9 163 612	6 753 338	9 609 134
Current liabilities					
Loans from credit institutions	16	1 838 028	2 615 278	1 258 152	1 790 189
Finance lease liabilities	17	18 520	26 352	55 681	79 227
Prepayments received from customers		37 672	53 602	41 840	59 533
Trade and other payables	20	4 186 141	5 956 342	4 555 589	6 482 019
Payables to related companies		293 008	416 913	183 668	261 336
Taxes payable	18	433 881	617 357	486 689	692 496
Corporate income tax	18	411 974	586 186	469 760	668 408
·		114 775	163 310	-	-
Accrued liabilities	19	442 422	629 510	1 601 469	2 278 685
TOTAL	•	7 776 421	11 064 850	8 652 847	12 311 892
TOTAL LIABILITIES	•	14 216 644	20 228 462	15 406 185	21 921 026
TOTAL EQUITY AND LIABILITIES		45 383 551	64 574 976	38 915 638	55 371 964

The accompanying notes form an integral part of these financial statements.

For the Board of JSC Olainfarm:

Jelena Borcova Member of the Board OlainFam

31 August 2012

Consolidated statement of cash flow

	2012.II.quarter		2011.II.quarter	
	LVL	EUR	LVL	EUR
Cash flows to/from operating activities				
(Loss)/ Profit before taxes	4 235 731	6 026 902	3 954 218	5 626 345
Adjustments for:				
Amortisation and depreciation	1 007 554	1 433 620	939 792	1 337 204
Loss on sale/ disposal of property, plant and equipment	13 589	19 335	12 319	17 528
Increase/ (decrease) in allowances	21 962	31 249	(291)	(414)
Incom from investing activities	-	-	220	313
Interest expences	97 843	139 218	135 489	192 783
Interest receivable	(5 687)	(8 092)	(21 482)	(30 566)
Operating cash flows before working capital changes	5 370 992	7 642 233	5 020 265	7 143 194
Decrease in inventories	(1 031 618)	(1 467 860)	214 986	305 898
Decrease in receivables and prepaid expence	(858 436)	(1 221 444)	(3 381 323)	(4 811 189)
Increase/ (decrease) in payables and prepayments received	(409 878)	(583 204)	1 329 305	1 891 431
Cash generated from operations	3 071 060	4 369 725	3 183 233	4 529 333
Interest paid	(97 843)	(139 218)	(98 694)	(140 429)
Corporate income tax paid	(765 188)	(1 088 764)	(586 605)	(834 664)
Net cash flows to/ from operating activities	2 208 029	3 141 742	2 497 934	3 554 240
Cash flows to/from investing activities				
Purchase of property, plant and equipment	(1 617 677)	(2 301 747)	(985 106)	(1 401 680)
Prepayments for investments	-	-	3 500	4 980
Acquistion of subsidiary	(739 196)	(1 051 781)	-	-
Proceeds from sale of intangible assets and property, plant and equipment	245	349	18 395	26 174
Interest receivable	82	117	1 263	1 797
Loans granted	(511 825)	(728 261)	(181 758)	(258 618)
Net cash flows to/from investing activities	(2 868 371)	(4 081 324)	(1 143 706)	(1 627 347)
Cash flows to/from financing activities				
Proceeds from issue of shares	-	-	(352 127)	(501 032)
Borrowings repaid	(654 465)	(931 220)	(673 170)	(957 835)
Proceeds from borrowings	801 474	1 140 395	-	-
Net cash flows to/from financing activities	147 009	209 175	(1 025 297)	(1 458 866)
Change in cash	(513 333)	(730 407)	328 931	468 027
Cash at the begining of the year	1 525 397	2 170 444	494 495	703 603
Cash at the and of the year	1 012 064	1 440 037	823 426	1 171 630

The accompanying notes form an integral part of these financial statements.

Statement of consolidated changes in equity

	Share capital	Share capital	Share premium	Share premium	Retained earnings/ (Accumulated deficit)	Retained earnings/ (Accumulated deficit)	Total	Total
	LVL	EUR	LVL	EUR	LVL	EUR	LVL	EUR
Balance as at 31 December 2009	14 085 078	20 041 260	1 759 708	2 503 839	1 266 810	1 802 508	17 111 596	24 347 607
Loss for the reporting year	-	-	-	-	3 539 450	5 036 184	3 539 450	5 036 184
Balance as at 31 December 2010	14 085 078	20 041 260	1 759 708	2 503 839	4 806 260	6 838 692	20 651 046	29 383 791
Loss for the reporting year	-	-	-	-	1 719 093	2 446 049	1 719 093	2 446 049
Balance as at 31 December 2011	14 085 078	20 041 260	1 759 708	2 503 839	11 369 565	16 177 434	27 214 351	38 722 533
Loss for the reporting year	-	-	-	-	3 692 776	3 415 577	3 692 776	3 415 577
Ilmas aptieka profit correction	-	-	-	-	259 410	369 107	259 410	369 107
Balance as at 30 June 2012	14 085 078	20 041 260	1 759 708	2 503 839	15 321 751	19 962 118	31 166 537	42 507 217

The accompanying notes form an integral part of these financial statements.

Notes to the consolidated financial statements

1. Corporate information

The principal activities of Olainfarm Group (hereinafter, the Group) are manufacturing and distribution of chemical and pharmaceutical products.

The Parent Company of the Group, JSC Olainfarm (hereinafter, the Parent Company) was registered with the Republic of Latvia Enterprise Register on 10 June 1991 (re-registered on 27 March 1997) and with the Republic of Latvia Commercial Register on 4 August 2004.

The shares of the Parent Company are listed on Riga Stock Exchange, Latvia.

These consolidated financial statements were approved by the Board on 31 August 2012

The Parent Company's shareholders have the power to amend the consolidated financial statements after the issue.

2. Summary of significant accounting policies

Basis of preparation

The consolidated financial statements have been prepared on a historical cost basis. The consolidated financial statements are presented in lats (LVL), the monetary unit of the Republic of Latvia.

The consolidated financial statements of JSC Olainfarm and all its subsidiaries have been prepared in accordance with International Financial Reporting Standards (IFRS), as adopted by the EU.

Foreign currency translation

The functional and reporting currency of companies of the Group is the Lat (LVL). All transactions denominated in foreign currencies are converted into Lats at the Bank of Latvia rate of exchange prevailing on the day the transaction took place. Gains and losses resulting from the settlement of such transactions and from the translation of monetary assets and liabilities denominated in foreign currencies are recognized in the statement of comprehensive income. At the year end foreign currency financial assets and liabilities are translated at the Bank of Latvia rate of exchange ruling at 31 December, and all associated exchange differences are dealt with through the statement of comprehensive income.

Exchange rates against the USD and EUR in the last two years have been:

	<u>30/06/2012</u>	30/06/2011
EUR	0.702804	0.702804
USD	0,562	0,489
RUB	0,0171	0,0174

3. Net sales

		2012.II.qu	2011.II.quarter		
By business segments		LVL	EUR	LVL	EUR
Finished form medicine		20 428 352	29 066 926	16 403 252	23 339 725
Chemicals		2 249 230	3 200 366	1 427 282	2 030 839
	TOTAL:	22 677 582	32 267 292	17 830 534	25 370 564

		2012.II.qu	2011.II.quarter		
By geographical segments		LVL	EUR	LVL	EUR
CIS		18 542 424	26 383 492	14 515 877	20 654 233
Europe		1 565 366	2 227 315	1 538 138	2 188 574
Latvia		1 283 413	1 826 132	1 069 569	1 521 859
Baltic states (Lithuania and Estonia)		257 233	366 010	272 248	387 374
Other		1 029 146	1 464 343	434 701	618 524
	TOTAL:	22 677 582	32 267 292	17 830 534	25 370 564

4. Other operating income

		2012.II.qu	arter	2011.II.qu	ıarter
		LVL	EUR	LVL	EUR
Other operating income		341 383	485 744	42 561	60 559
Income of services*		84 513	120 251	31 834	45 296
Lease of premises		36 465	51 885	21 788	31 002
Incomes from catering services		22 983	32 702	13 807	19 646
Gains from sale of non-current assets		13 501	19 210	29 357	41 772
Sale of current assets		6 344	9 027	5 937	8 448
Treatment of waste water		2 415	3 436	1 654	2 354
Incomes of wholesale trade		-	-	138 280	196 755
Royalty		-	-	1 087	1 546
	TOTAL:	507 604	722 255	286 307	407 378

Income from services includes the analysis of preparations based on customer's orders.

5. Other operating expense

	2012.11.	quarter	2011.II.qu	II.quater	
	LVL	EUR	LVL	EUR	
Marketing expense	5 191 850	7 387 337	5 133 417	7 304 195	
Sales commissions	34 468	49 044	37 470	53 315	
Transportation expense	84 639	120 430	62 543	88 991	
Other distribution costs	313 902	446 642	77 713	110 575	
Expert analysis of medicines	22 921	32 614	35 086	49 923	
Total distribution costs:	5 647 780	8 036 067	5 346 229	7 606 999	
Car fleet maintenance	183 869	261 622	123 050	175 085	
Security	106 298	151 248	101 662	144 652	
Business trips	178 892	254 540	82 486	117 368	
Representation ex pense	68 585	97 588	82 443	117 306	
Information and business consulting	61 307	87 232	68 240	97 097	
Write-offs of current assets	252 566	359 369	64 199	91 347	
Expense of registration of products	36 482	51 909	62 201	88 504	
Social infrastructure	57 706	82 108	39 541	56 262	
Flowers and gifts	38 093	54 201	35 910	51 096	
Other tax es	38 235	54 404	34 802	49 519	
Communications expense	43 973	62 568	34 456	49 027	
Write-offs and disposal of tangible assets	12 419	17 671	28 747	40 903	
Education	45 556	64 820	27 466	39 081	
Donations	51 100	72 709	25 413	36 160	
Insurance	62 822	89 388	23 431	33 340	
Legal and audit expense	42 700	60 757	19 941	28 374	
Current repairs	6 835	9 725	18 259	25 981	
Laboratory tests	7 038	10 014	17 428	24 797	
Stock quote expense	14 854	21 135	15 879	22 594	
Office expense	21 683	30 852	14 087	20 043	
Expense of preservation of the environment	17 488	24 883	14 044	19 983	
Bank charges	24 245	34 498	-	-	
Allowances to staff	19 505	27 753	-	-	
New product research and development costs	59 336	84 428	-	-	
Other operating expense	553 386	787 398	268 857	382 545	
TOTAL:	7 652 753	10 888 887	6 548 771	9 318 062	

6. Financial income

		2012.II.qu	arter	2011.II.qu	arter
		LVL	EUR	LVL	EUR
Interest accrued on bank account balances		21 870	31 118	-	-
Currency exchange gain, net		5 605	7 975	20 450	29 098
Received penalties		230	327	-	-
Loan interest payments		82	117	1 032	1 468
	TOTAL:	27 787	39 537	21 482	30 566

7. Financial expense

		2012.II.quarter		2011.II.qu	arter
		LVL	EUR	LVL	EUR
Loan interest expenses		97 843	139 218	135 493	192 788
Penalties paid for late payments		5 594	7 960	7 308	10 399
Currency exchange loss, net		-	-	17 655	25 121
	TOTAL:	103 437	147 178	160 456	228 308

8. Staff costs and number of employees

		2012.II.qu	arter	2011.II.qu	arter
		LVL	EUR	LVL	EUR
Wages and salaries		3 676 043	5 230 538	2 822 997	4 016 763
Statutory social insurance contributions		857 163	1 219 633	659 272	938 060
	TOTAL:	4 533 206	6 450 171	3 482 269	4 954 822

	2012.II.qu	arter	2011.II.qu	arter	
	LVL	EUR	LVL	EUR	
Management of the Group					
Wages and salaries	312 152	444 152	270 415	384 766	
Statutory social insurance contributions	73 878	105 119	64 929	92 386	
Board Members					
Wages and salaries	267 371	380 435	279 018	397 007	
Statutory social insurance contributions	64 410	91 647	67 215	95 638	
<u>Council Members</u>					
Wages and salaries	36 000	51 223	54 000	76 835	
Statutory social insurance contributions	8 672	12 339	13 009	18 510	
TOTA	AI: 762 483	1 084 916	748 586	1 065 142	

	30/06/2012	30/06/2011
Average number of employees during the reporting year	1037	815

9. Basic and diluted earnings per share

Earnings per share are calculated by dividing the net result for the year after taxation attributable to shareholders by the weighted average number of shares in issue during the year. The table below presents the income and share data used in the computations of basic earnings per share:

		2012.II.quarter		2011.II.q	_l uarter
		LVL	EUR	LVL	EUR
Net result attributable to shareholders		3 692 776	5 254 347	3 210 534	4 568 178
Weighted average number of ordinary shares		14 085 078	14 085 078	14 085 078	14 085 078
	Earnings per share	0.262	0.373	0.228	0.324

The Parent Company has no potential dilutive ordinary shares and therefore diluted earnings per share are the same as the basic earnings per share.

10. Intangible assets

			Produ	ıction				
	Goodwill technologies Other intangible			gible assets	ts TOTAL			
	LVL	EUR	LVL	EUR	LVL	EUR	LVL	EUR
Acquisition value as at 31/12/2010	503 930	717 028	6 222 789	8 854 231	837 923	1 192 257	7 564 642	10 763 516
2011								
Il quarter Additions	-	-	3 381	4 811	108 987	155 075	112 368	159 887
Acquisition value as at 30/06/2011	503 930	717 028	6 226 170	8 859 042	946 910	1 347 332	7 677 010	10 923 403
Accumulated amortisation as at 31/12/2010			461 569	656 754	320 990	456 727	782 559	1 113 481
2011								
Il quarter Amortisation	-	-	78 409	111 566	79 825	113 581	158 234	225 147
Accumulated amortisation as at 30/06/2011			539 978	768 319	400 815	570 308	940 793	1 338 626
Net carrying amount as at 30/06/2011	503 930	717 028	5 686 192	8 090 722	546 095	777 023	6 736 217	9 584 773

		Good	lwill	Good	lwill	Produc		Other int		тот	ΔI
		LVL	EUR	LVL	EUR	LVL	EUR	LVL	EUR	LVL	EUR
Acquisitio	on value as at 31/12/2011	1 417 185	2 016 473	3 980 000	5 663 030	2 940 990	4 184 652	1 000 098	1 423 010	9 338 273	13 287 164
	Additions	-	-	-	-	11 448	16 289	271 078	385 708	282 526	401 998
2012 II.quarter	Acquisition value as at 30/06/2012 of of subsidiary	760 917	1 082 687	304 000	432 553	-	-	-	-	1 064 917	1 515 240
	Disposals	-	-	-	-	_	-	(13 245)	(18 846)	(13 245)	(18 846)
Acquisitio	on value as at 30/06/2012	2 178 102	3 099 160	4 284 000	6 095 583	2 952 438	4 200 941	1 257 931	1 789 874	10 672 471	15 185 557
Accumula	ted amortisation as at 31/12/2011	-			•	1 551 402	2 207 446	400 993	570 562	1 952 395	2 778 008
2012	Amortisation	-	-	-	-	80 428	114 439	95 982	136 570	176 410	251 009
II.quarter	Amortisation of disposals	-	-	-	-	-	-	(13 139)	(18 695)	(13 139)	(18 695)
Accumula	ted amortisation as at 30/06/2012					1 631 830	2 321 885	483 836	688 437	2 115 666	3 010 322
•	ng amount as at 31/12/2011 ng amount as at 30/06/2012	1 417 185 2 178 102	2 016 473 3 099 160	3 980 000 4 284 000	5 663 030 6 095 583	1 389 588 1 320 608	1 977 206 1 879 056	599 105 774 095	852 450 1 101 438	7 385 878 8 556 805	10 509 158 12 175 237

11. Property, plant and equipment

LVL

Acquisitio	on value as at 31/12/2010	Land 55 928	Buildings and constructions 13 040 855	Equipment and machinery 11 401 009	Other tangible assets 2 232 933	Construction in progress	TOTAL 26 744 359
	Additions	10 000	-	264 805	94 554	204 174	573 533
2011.	Liquidation	-	(271)	(28 801)	(198 068)	(1 967)	(229 107)
Il quarter	Reclassification of reversed impairment	-	-	(5 546)	5 546	-	-
	Reclassification	-	2 186	-	-	(2 186)	-
	Reversed impairment	-	-	291	-	-	291
Acquisitio	n value as at 30/06/2011	65 928	13 042 770	11 631 758	2 134 966	213 656	27 089 077
Accumula	ted depreciation as at 31/12/2010	-	6 957 958	9 108 985	1 562 532	-	17 629 475
2011.	Depreciation	-	263 669	373 241	144 647	-	781 558
II quarter	Depreciation of disposals	-	(271)	(28 267)	(169 855)	-	(198 393)
Accumula	ted depreciation as at 30/06/2011	-	7 221 357	9 453 959	1 537 324		18 212 639
Net carryii	ng amount as at 30/06/2011	65 928	5 821 413	2 177 799	597 642	213 656	8 876 438

					Other		
			Buildings and	Equipment and	tangible	Construction in	
		Land	constructions	machinery	assets	progress	TOTAL
Acquisition value as at 31/12/2011		109 826	14 027 907	12 402 816	2 462 099	854 852	29 857 500
Acqu 2012 II.quarter subsi Liqui	Additions	4 847	44 739	517 160	386 150	836 343	1 789 239
	Acquisition value as at 30/06/2012 of of subsidiary	-	4 220	-	2 143	-	6 363
	Liquidation	-	(29 970)	(113 507)	(104 352)	(1 310)	(249 139)
	Reclassification of reversed impairment	-	-	1 686	-	-	1 686
	Reclassification	-	997 091	900	(900)	(997 091)	-
Acquisition value	e as at 30/06/2012	114 673	15 043 987	12 809 055	2 745 140	692 794	31 405 649
Accumulated dep	preciation as at 31/12/2011	-	7 341 828	9 764 987	1 650 048	-	18 756 863
2012 II guartar	Depreciation	-	297 425	416 282	160 926	-	874 633
2012 II.quarter	Depreciation of disposals	-	(25 601)	(112 338)	(97 472)	-	(235 411)
Accumulated dep	Accumulated depreciation as at 30/06/2012		7 613 652	10 068 931	1 713 502	-	19 396 085
, ,	unt as at 31/12/2011 unt as at 30/06/2012	109 826 114 673	6 686 079 7 430 335	2 637 829 2 740 124	812 051 1 031 638	854 852 692 794	11 100 637 12 009 564

Address: Rūpnīcu iela 5, Olaine, LV-2114 Unified registration number: 40003007246

11.Property, plant and equipment (cont'd)

EUR

		Land	Buildings and constructions	Equipment and machinery	Other tangible assets	Construction in progress	TOTAL
Acquisitio	n value as at 31/12/2010	79 578	18 555 465	16 222 174	3 177 177	19 401	38 053 795
2011.	Additions	-	-	93 349	48 927	74 870	217 146
	Liquidation	-	(296)	(4 801)	(230 151)	(1 884)	(237 132)
I quarter	Reclassification	-	2 499	909	(909)	(2 499)	-
Acquisitio	n value as at 31/03/2011	79 578	18 557 668	16 311 631	2 995 044	89 889	38 033 810
Accumula	ted depreciation as at 31/12/2010	•	9 900 282	12 960 918	2 223 282	-	25 084 482
2011.	Depreciation	-	187 581	266 115	105 908	-	559 604
	Depreciation of disposals	-	(296)	(4 501)	(215 850)	-	(220 646)
l quarter	Reversed impairment			911			
Accumula	ted depreciation as at 31/03/2011	-	10 087 566	13 223 444	2 112 429	-	25 423 439
Net carryii	ng amount as at 31/03/2011	79 578	8 470 103	3 088 189	882 614	89 889	12 610 374

					Other		
			Buildings and	Equipment and	tangible	Construction in	
		Land	constructions	machinery	assets	progress	TOTAL
Acquisition v	Acquisition value as at 31/12/2011		19 959 913	17 647 617	3 503 251	1 216 345	42 483 395
2012 I.quarter subsidiary Liquidation	Additions	6 897	63 658	735 852	549 442	1 190 009	2 545 858
	Acquisition value as at 31/03/2012 of of subsidiary	-	6 004	-	3 049	-	9 054
	Liquidation	-	(42 643)	(161 506)	(148 480)	(1 864)	(354 493)
	Reclassification of reversed impairment	-	-	2 399	-	-	-
	Reclassification	-	1 418 733	1 281	(1 281)	(1 418 733)	-
Acquisition v	alue as at 31/03/2012	163 165	21 405 665	18 225 644	3 905 982	985 757	44 686 213
Accumulated	depreciation as at 31/12/2011	-	10 446 480	13 894 325	2 347 807	-	26 688 612
2012 Laurenton	Depreciation	-	423 197	592 316	228 977	-	1 244 491
2012 I.quarter	Depreciation of disposals	-	(36 427)	(159 843)	(138 690)	-	(334 960)
Accumulated	depreciation as at 31/03/2012	-	10 833 251	14 326 798	2 438 094		27 598 143
	amount as at 31/12/2011 amount as at 31/03/2012	156 268 163 165	9 513 433 10 572 414		1 155 444 1 467 888	1 216 345 985 757	15 794 783 17 088 070

There is a difference of LVL 11 781 between total depreciation and amortisation under the income statement and the total depreciation and amortisation stated in Notes 10 and 11. Difference is explained as depreciation of the property, plant and equipment in the cafe and the canteen - LVL 11 781 which was disclosed in the income statement as other operating .

Address: Rūpnīcu iela 5, Olaine, LV-2114 Unified registration number: 40003007246

12. Inventories

		30.06.2012		30.06.2	011
		LVL	EUR	LVL	EUR
Work in progress (at cost)		3 908 858	5 561 803	3 848 741	5 476 265
Finished goods and goods for resale (at cost)*		3 537 014	5 032 718	2 264 738	3 222 432
Raw materials (at cost)		1 440 844	2 050 136	987 104	1 404 522
Prepayments for goods		127 575	181 523	92 571	131 717
Goods in transit		-	-	70 068	99 697
	TOTAL:	9 014 291	12 826 180	7 263 222	10 334 633
Allowances for raw materials		(150 654)	(214 361)	(215 679)	(306 885)
Allowances for finished goods and goods for resale		(289 253)	(411 570)	(319 590)	(454 737)
Allowances for work in progress		(263 854)	(375 430)	(182 835)	(260 152)
	TOTAL:	(703 761)	(1 001 361)	(718 104)	(1 021 772)
	TOTAL:	8 310 530	11 824 819	6 545 118	9 312 864

^{*} As at 30 June 2012, the Group's inventories comprised goods on consignment in the amount of LVL 49 203 (30/06/2011: LVL 197 110).

13. Trade receivables

		30.06.2	012	30.06.2011	
		LVL	EUR	LVL	EUR
Trade receivables		13 420 125	19 095 118	11 078 142	15 762 775
Allowances for doubtful trade receivables		(107 597)	(153 097)	(131 114)	(186 559)
	TOTAL:	13 312 528	18 942 021	10 947 028	15 576 217

14. Cash and short term deposits

	30.06.20	30.06.2012		011
	LVL	EUR	LVL	EUR
Cash at banks and on hand	1 012 064	1 440 037	823 426	1 171 630
	1 012 064	1 440 037	823 426	1 171 630

	30	30.06.2012			2011
	Foreigr	า		Foreign	
Cash by currency profile:	currenc	y	LVL	currency	LVL
RUB	7 613 05	51	130 183	-	-
LVL		-	625 075	-	188 923
EUR	302 76	60	212 781	861 010	605 121
USD	78 33	37	44 025	60 087	29 382
	KOPĀ:	-	1 012 064		823 426

15. Share capital

The share capital of the Parent Companyon 30/06/2012 is LVL 14 085 078 (30/06/2011: LVL 14 085 078) and consists of 14 085 078 (30/06/2011: 14 085 078) shares. The par value of each share is LVL 1.

All 14 085 078 shares are ordinary publicly traded dematerialized voting shares to bearer.

Address: Rūpnīcu iela 5, Olaine, LV-2114 Unified registration number: 40003007246

16. Loans from credit institutions

			Interest rate (%)		30.06.2012. LVL	30.06.2012. EUR	30.06.2011. LVL	30.06.2011. EUR
Non-current:	Amount		30/06/ 2012	Maturity		-		
Loan from AS SEB			EURIBOR					
banka	4 800 000	EUR	(3-month)+1.1%	01.11.2014	3 716 172	5 287 637	-	-
Loan from AS SEB			EURIBOR					
banka	7 011 574	EUR	(3-month)+1.2%	29.09.2014	1 572 690	2 237 736	2 830 842	4 027 925
				TOTAL:	5 288 862	7 525 373	2 830 842	4 027 925
			Interest rate (%)		30.06.2012.	30.06.2012.	30.06.2011.	30.06.2011.
			Interest rate (%) as at		30.06.2012. LVL	30.06.2012. EUR	30.06.2011. LVL	30.06.2011. EUR
Current:	Amount		, ,	Maturity				
Current: Loan from AS SEB	Amount		as at	Maturity				
	Amount 4 800 000	EUR	as at 30/06/ 2012	Maturity 01.11.2014				
Loan from AS SEB		EUR	as at 30/06/ 2012 EURIBOR	,	LVL	EUR		
Loan from AS SEB banka		EUR EUR	as at 30/06/ 2012 EURIBOR (3-month)+1.1%	,	LVL	EUR		
Loan from AS SEB banka Loan from AS SEB	4 800 000		as at 30/06/ 2012 EURIBOR (3-month)+1.1% EURIBOR	01.11.2014	LVL 401 602	EUR 571 429	LVL -	EUR
Loan from AS SEB banka Loan from AS SEB banka	4 800 000		as at 30/06/ 2012 EURIBOR (3-month)+1.1% EURIBOR (3-month)+1.2%	01.11.2014	LVL 401 602	EUR 571 429	LVL -	EUR

Interest payable is normally settled quarterly throughout the financial year.

17. Finance lease liabilities

		30.06.2012. LVL		30.06.2012. EUR		30.06.2011. LVL		30.06.2011. EUR	
		Non-curren	Current	Non-curren	Current	Non-curren	Current	Non-curren	Current
Finance lease liabilities to SIA SEB Unilīzings, EUR		2 923	14 618	4 159	20 800	12 839	55 681	18 268	79 227
Finance lease liabilities to SIA SEB Unilizings, LVL		13 887	3 902	19 759	5 552	-	-	-	-
	TOTAL:	16 810	18 520	23 918	26 352	12 839	55 681	18 268	79 227

The interest rate on the finance leases ranges from 2.47% to 4.73%. Interest rate is normally revised quarterly throughout the financial year. The net carrying amount of the property, plant and equipment held under finance lease is disclosed in Note 11.

Future minimum lease payments for the above finance leases can be specified as follows:

	30.06.2012.		30.06	30.06.2012.		30.06.2011.		2011.
		Present		Present		Present		Present
	Minimum	value of	Minimum	value of	Minimum	value of	Minimum	value of
	payments	payments	payments	payments	payments	payments	payments	payments
	LVL	LVL	EUR	EUR	LVL	LVL	EUR	EUR
Within one year	19 235	18 520	27 369	26 352	57 715	55 681	82 121	79 227
Between one and five years	17 472	16 810	24 860	23 918	13 153	12 839	18 715	18 268
Total minimum lease payments	36 707	35 330	52 229	50 270	70 868	68 520	100 835	97 494
Less amounts representing finance charges	(1 377)	-	(1 959)	-	(2 348)	-	(3 341)	-
Present value of minimum lease payments	35 330	35 330	50 270	50 270	68 520	68 520	97 494	97 494

^{*} As at 30 June 2012, all the non-current and current assets owned by the Parent Company were pledged as a security for the loan received. The pledge agreements are registered with the Commercial Pledge Registry.

18. Taxes payable/ receivable

	30.06.2012.	30.06.2012.	30.06.2011.	30.06.2011.
	LVL	EUR	LVL	EUR
Corporate income tax	(411 974)	(586 186)	(469 760)	(668 408)
Statutory social insurance contributions *	(299 418)	(426 033)	(325 033)	(462 480)
Personal income tax *	(128 225)	(182 448)	(149 810)	(213 160)
Natural resource tax	(5 596)	(7 962)	(3 970)	(5 649)
Real estate tax *	(380)	(541)	(7 659)	(10 898)
Value added tax	(263)	(374)	(217)	(309)
Value added tax	151 223	215 171	191 458	272 420
TOTAL:	(694 633)	(988 373)	(764 991)	(1 088 484)
Total liabilities:	(845 856)	(1 203 544)	(956 449)	(1 360 904)
Total assets:	151 223	215 171	191 458	272 420

19. Accrued liabilities

	30.06.20)12.	30.06.2011.		
	LVL	EUR	LVL	EUR	
Vacation pay reserve	355 760	506 201	341 164	485 433	
Accruals for electricity and gas	42 040	59 818	75 662	107 657	
Provisions for penalties related to taxes (see Note 25)	22 590	32 143	9 330	13 275	
Other accrued liabilities	22 032	31 349	8 132	11 570	
Accruals for marketing services	-	-	949 020	1 350 334	
Accrued interest for purchase of long term investment	-	-	218 162	310 416	
TOTAL:	442 422	629 511	1 601 469	2 278 685	

20. Trade and other payables

		30.06.2	012.	30.06.2011.		
		LVL	EUR	LVL	EUR	
Trade and other payables		3 753 136	5 340 232	4 238 342	6 030 617	
Wages and salaries		385 077	547 915	308 591	439 086	
Other paybles		47 928	68 195	8 656	12 316	
	TOTAL:	4 186 141	5 956 342	4 555 589	6 482 019	

21. Segment information

For management purposes group is organized into business units based on its products, and has two reportable operating segments as follows:

The finished form medicine segment represents tablets, capsules, ampoules and sachets, namely the products ready for final consumption by end users.

The chemicals segment is sales of chemicals to the clients of the Group for further processing, eventually into finished form medicines. Production of both segments is separated.

Under the segment "Chemicals" the Group has stated revenues from sale of chemical and pharmaceutical substances only to customers outside the Group. However, most of the chemicals are used to produce the final dosage forms within the Group and revenues generated by them do cover the resources invested into fixed assets used for chemical production. The Group does not keep separate books by segments. The segment "Other" relates primarily to matters that are managed on a group basis.

21. Segment information (cont'd)

LVL

	Finished form medicine		Pharmacy wholesale		Chemicals		Pharmacy retail		Unallocated		Total	
	30.06.2012.	30.06.2011.	30.06.2012.	30.06.2011.	30.06.2012.	30.06.2011.	30.06.2012.	30.06.2011.	30.06.2012.	30.06.2011.	30.06.2012.	30.06.2011.
Assets												
Intangible assets	2 345 530	4 652 916			2 173 887	2 328 690	3 980 000	-	234 010	85 901	8 733 427	7 067 507
Tangible assets	6 813 720	5 992 843	1 116	-	3 510 098	2 451 349	296 063	-	1 473 332	899 969	12 094 329	9 344 162
Financial assets	-	-		-	-	-	-	-	1 007	1 650	1 007	1 650
Inventories	5 035 841	4 645 070	22 574	-	2 594 221	1 900 047	657 894	-	-	-	8 310 530	6 545 117
Receivables	12 294 390	12 830 390	83 165	-	796 074	2 138 870	311 783	-	1 746 783	164 516	15 232 194	15 133 776
Cash	-	-		-	-	-	279 300	-	732 764	823 426	1 012 064	823 426
Total assets	26 489 481	28 121 219	106 855	•	9 074 280	8 818 956	5 525 040	•	4 187 896	1 975 462	45 383 551	38 915 638
Equity and liabilities												
Total equity	-	-	-	-	-	-	-	-	31 166 537	23 509 453	31 166 537	23 509 453
Minority interest	-	-		-	-	-	-	-	370	-	370	-
Deffered income tax liability	-	-		-	-	-	620 680	-	513 871	916 370	1 134 551	916 370
Loans from credit institution	4 703 747	2 901 959		-	2 423 143	1 187 035	-	-	-	-	7 126 890	4 088 994
Other loans	20 381	432 035			10 500	176 722	4 449	-	-	-	35 330	608 757
Taxes payable	513 453	678 792		-	264 506	277 657	61 657	-	6 239	-	845 855	956 449
Prepayments received from customers	13 811	11 830			23 862	30 000	-	-	-	10	37 673	41 840
Trade payables	2 027 032	4 974 030	153 940		985102	2 034 608	1 134 842	-	-	-	4 300 916	7 008 639
Payables to related companies	193 385	130 349			99 623	53 319	-	-	-	-	293 008	183 668
Accrued liabilities	-	-			-	-	84 028	-	358 394	1 601 469	442 422	1 601 469
Total equity and liabilities	7 471 810	9 128 995	153 940	•	3 806 735	3 759 341	1 905 656		32 045 411	26 027 302	45 383 551	38 915 638
Income statement												
Netturnover	16 960 207	16 403 252	276 590	-	2 248 852	1 427 282	3 191 933	-	-	-	22 677 582	17 830 534
Changes in stock of finished goods and work in												
progress	260 178	(154 126)		-	134 031	(63 045)	-	-	-	-	394 209	(217 171)
Other operating income	-	-			-	-	12 250	-	495 354	286 307	507 604	286 307
Cost of materials	(2 408 040)	(2 014 769)		-	(1 240 505)	(824 134)	(2 394 247)	-	-	-	(6 042 792)	(2 838 903)
Staff costs	(2 672 139)	(2 471 366)		-	(1 376 557)	(1 010 903)	(442 660)	-	(41 850)	-	(4 533 206)	(3 482 269)
Depreciation/ amortisation and write-offs	(622 049)	(630 407)	(143)		(320 450)	(257 865)	(23 319)	-	(73 301)	(48 263)	(1 039 262)	(936 535)
Other operating expense	(4 677 074)	(4 647 663)	•		(2 409 402)	(1 901 108)	(270 544)	-	(295 734)	-	(7 652 753)	(6 548 771)
Financial income	-	-			-		•		27 787	21 482	27 787	21 482
Financial expenses	-			-	-		-		(103 437)	(160 456)	(103 437)	(160 456)
Corporate income tax	-			-	-		(1 432)	-	(541 524)	(743 684)	(542 956)	(743 684)
Net profit/ (loss) for the year	6 841 083	6 484 921	276 447		(2 964 030)	(2 629 773)	71 981		(532 705)	(644 614)	3 692 776	3 210 534

Address: Rūpnīcu iela 5, Olaine, LV-2114 Unified registration number: 40003007246

21. Segment information (cont'd)

EUR

Lon	Finish ad fama madish a		Dhamaahalaaala		Chamiaala		Dharmaay ratail		المعامم مالمسا		Total	
	Finished form medicine				Chemicals		Pharmacy retail 30.06.2012. 30.06.2011.		Unallocated		Total 20.00.2044	
	30.06.2012.	30.06.2011.	30.06.2012.	30.06.2011.	30.06.2012.	30.06.2011.	30.06.2012.	30.06.2011.	30.06.2012.	30.06.2011.	30.06.2012.	30.06.2011.
Assets												
Intangible assets	3 337 389	3 093 162	3 313 427	5 663 030	3 313 427	3 313 427	5 663 030	-	332 966	122 226	12 426 547	10 056 156
Tangible assets	9 695 050	4 994 420	3 487 955	421 260	4 994 420	3 487 955	421 260	-	2 096 363	1 280 541	17 208 680	13 295 545
Financial assets	-	-	-	-	-	-	-	-	1 433	2 348	1 433	2 348
Inventories	7 165 356	3 691 244	2 703 523	936 099	3 691 244	2 703 523	936 099	-	-	-	11 824 819	9 312 862
Receivables	17 493 340	1 132 711	3 043 338	443 627	1 132 711	3 043 338	443 627	-	2 485 448	234 085	21 673 459	21 533 424
Cash		-	-	397 408	-	-	397 408	-	1 042 629	1 171 630	1 440 037	1 171 630
Total assets	37 691 135	40 012 890	152 041	•	12 911 537	12 548 244	7 861 424	•	5 958 839	2 810 829	64 574 975	55 371 965
Equity and liabilities												
Total equity	-		-	-	-	-	-	-	44 345 987	33 450 938	44 345 987	33 450 939
Minority interest	-	-	-	-	-	-	-	-	526	-	526	-
Deffered income tax liability	-	-	-	-	-	-	883 148	-	731 173	1 303 877	1 614 321	1 303 877
Loans from credit institution	6 692 830	4 129 116	-	-	3 447 821	1 688 999	-	-	-	-	10 140 651	5 818 114
Other loans	29 000	614 730	-	-	14 939	251 453	6 330	-	-	-	50 270	866 183
Taxes payable	730 578	965 834	-	-	376 358	395 070	87 730	-	8 877	-	1 203 543	1 360 904
Prepayments received from customers	19 651	16 833	-		33 953	42 686	-	-	-	14	53 604	59 533
Trade payables	2 884 207	7 077 407	219 037	-	1 401 674	2 894 986	1 614 735	-	-		6 119 652	9 972 395
Payables to related companies	275 162	185 470	-	-	141 750	75 866	-	-	-		416 913	261 336
Accrued liabilities	-	-	-	-	-	-	119 561	-	509 949	2 278 685	629 510	2 278 685
Total equity and liabilities	10 631 428	12 989 390	219 037	•	5 416 496	5 349 060	2 711 504	•	45 596 512	37 033 514	64 574 975	55 371 965
Income statement												
Net turnover	24 132 201	23 339 725	393 552	-	3 199 828	2 030 839	4 541 711	-	-	-	32 267 292	25 370 564
Changes in stock of finished goods and												
work in progress	24 132 201	(219 302)	-	-	190 709	(89 705)	-	-	-		560 909	(309 006)
Other operating income		-		-	-		17 430	-	704 825	407 378	722 255	407 378
Cost of materials	(3 426 332)	(2 866 758)	-	-	(1 765 080)	(1 172 637)	(3 406 707)	-	-		(8 598 119)	(4 039 395)
Staff costs	(3 802 112)	(3 516 437)	-	-	(1 958 664)	(1 438 385)	(629 848)	-	(59 547)		(6 450 171)	(4 954 822)
Depreciation/ amortisation and write-offs	(885 096)	(896 988)	(203)	-	(455 959)	(366 909)	(33 180)	-	(104 298)	(68 672)	(1 478 737)	(1 332 569)
Other operating expense	(6 654 876)	(6 613 029)	, ,		(3 428 269)	\ /	(384 949)		(420 792)	, ,	(10 888 887)	(9 318 062)
Financial income	-	•			-		•	•	(147 178)	30 566	39 537	30 566
Financial expenses					-				(147 178)	(228 308)	(147 178)	(228 308)
Corporate income tax					-		(2 038)		(770 519)	(1 058 167)	(772 557)	(1 058 167)
Net profit/ (loss) for the year	9 733 984	9 227 211	393 349		(4 217 435)	(3 741 830)			(757 971)	(917 203)	5 254 347	4 568 178

Segment assets do not include part of the intangible assets, tangible assets, inventories, receivables and financial assets and cash, as these assets are managed on a Group bases.

Segment liabilities do not include deferred tax liability and accrued liabilities, as these liabilities are managed on Group level.

Net profit for each operating segment does not include financial income and expenses and corporate income tax and deferred corporate income tax.

Geographic information

Major part of the Group assets (approx. 99%) is located in Latvia. For sales disclosed to external customers based on its geographical location, see Note 3.